New Prostate Cancer Medication Improves Survival in a Large Trial
A new drug from drug maker Medivation significantly improved survival in a large trial of men with advanced prostate cancer, researchers are reporting at a major cancer meeting. The advance is notable for the way it was developed — by a prominent academic researcher whose lab did the work with almost no help from industry scientists until late in the game. It is likely to reach the market much faster than if a big pharma company had been involved. Ron Winslow discusses on the News Hub.